Related Experiment Video
Updated: Apr 16, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
[Colonic ulcers associated with taking Kayexalate(®) (sodium polystyrene sulfonate): about two cases]
Bérengère Ponroy1, Marion Nadal1, Julien Nardoux2
1Service d'anatomie et de cytologie pathologiques, hôpital de la Source, 14, avenue de l'Hôpital, 45067 Orléans, France.
Abstract:
We report two cases of patients with chronic renal failure showing rectal bleeding due to digestive ulcers, associated with Kayexalate(®) alone. Kayexalate(®) crystals correspond to a typical histological picture and it is important to know how to identify them in order to discuss a possible pathogenicity.
More Related Videos
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

